Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study.

Objective: To evaluate long-term glycemic outcomes of continuous glucose monitoring (CGM) initiation within the first year of type 1 diabetes diagnosis.

Research Design And Methods: Patients with type 1 diabetes (N = 396) were divided into three groups: 1) CGM (CGM use within 1 year of diabetes diagnosis and continued through the study), 2) no-CGM (no CGM use throughout the study), and 3) new-CGM (CGM use after 3 years since diabetes diagnosis). Patients were followed up to 7 years.

Differentiating Diabetic Ketoacidosis and Hyperglycemic Ketosis Due to Cannabis Hyperemesis Syndrome in Adults With Type 1 Diabetes.

Objective: To differentiate diabetic ketoacidosis (DKA) from hyperglycemic ketosis due to cannabis hyperemesis syndrome (HK-CHS) in adults with type 1 diabetes.

Research Design And Methods: Of 295 adults with type 1 diabetes who were seen with DKA-related ICD-10 codes, 68 patients with 172 DKA events meeting the inclusion criteria were analyzed. Cannabis use was defined as a positive urine test result for cannabis.

Comparison of Cgmanalysis, a Free Open-Source Continuous Glucose Monitoring Data Management and Analysis Software, with Commercially Available CGM Platforms: Data Standardization for Diabetes Technology Research.

Cgmanalysis is an open-source software based on the R programming language for data management and descriptive analysis of data from continuous glucose monitoring (CGM). We sought to validate the summary measures calculated by cgmanalysis against the results from proprietary software associated with four CGM commercially available models. Two weeks of data from 188 patients with type 1 diabetes using commercially available CGMs.

Fracture risk assessment (FRAX) without BMD and risk of major osteoporotic fractures in adults with type 1 diabetes.

Objective: To evaluate the association between Fracture Risk Assessment Tool (FRAX) without bone mineral density (BMD) and risk for major osteoporotic fractures (MOF) in type 1 diabetes.

Methods: Subjects with type 1 diabetes and without diabetes from the 'Coronary Artery Calcification in Type 1 Diabetes' study were included. Risk for MOF was calculated using FRAX-based clinical risk factors and without BMD at visit 3 (2006-2008).

Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes.

Aim: To compare glycaemic metrics at 3 and 6 months in patients with type 1 diabetes on a 670G hybrid closed-loop (HCL) system after using a sensor-augmented pump (SAP) for at least 3 months.

Materials And Methods: A retrospective study from a centre that has the largest number of 670G users in the United States was conducted. Data from 202 SAP users were reviewed.

Bone Mineral Density across the Lifespan in Patients with Type 1 Diabetes.

Context: Fracture risk in people with type 1 diabetes (T1D) is higher than their peers without diabetes.

Objective: To compare bone mineral density (BMD) across the lifespan in individuals with T1D and age- and sex-matched healthy controls.

Design: Cross-sectional.